Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin

医学 不利影响 药代动力学 内科学 胃肠病学 外科
作者
Kenneth L. Duchin,Giorgio Senaldi,Vance Warren,Thomas C Marbury,Kenneth C. Lasseter,Hamim Zahir
出处
期刊:Clinical Drug Investigation [Adis, Springer Healthcare]
卷期号:38 (11): 1001-1009 被引量:16
标识
DOI:10.1007/s40261-018-0692-7
摘要

BACKGROUND AND OBJECTIVES: δ ligand being developed to treat neuropathic pain. A small fraction of mirogabalin is metabolized by the liver, where hepatic impairment may affect exposure. The objective of this phase I, open-label single-dose study was to determine if mild or moderate hepatic impairment alters the pharmacokinetics of mirogabalin. METHODS: Serial blood samples were collected for determination of maximum observed concentration, time to maximum concentration, and area under the concentration-time curve until the last quantifiable concentration of the active free form (A200-700) and inactive lactam metabolite (A204-4455) of mirogabalin. RESULTS: The A200-700 maximum observed concentration was similar in subjects with mild hepatic impairment but lower in subjects with moderate hepatic impairment vs. control subjects. The A204-4455 maximum observed concentration was lower in subjects with mild and moderate hepatic impairment vs. control groups. The A200-700 area under the concentration-time curve until the last quantifiable concentration was slightly lower in subjects with mild hepatic impairment and slightly higher in subjects with moderate hepatic impairment vs. control subjects. Peak A204-4455 levels were approximately 22% and 31% lower for subjects with mild and moderate hepatic impairment vs. control individuals, respectively. Exposure to A204-4455 was approximately 37% lower in subjects with mild hepatic impairment but unaffected in subjects with moderate hepatic impairment vs. control groups. Two subjects in the mild hepatic impairment group reported a treatment-emergent adverse event of mild somnolence. No serious or severe treatment-emergent adverse events, discontinuations as a result of treatment-emergent adverse events, or deaths were reported. CONCLUSIONS: Mild hepatic impairment resulted in lower A200-700 and A204-4455 exposure, while moderate hepatic impairment did not affect A200-700 exposure. Overall, mild-to-moderate hepatic impairment did not have a significant effect on mirogabalin exposure. A single 15-mg dose of mirogabalin was well tolerated by subjects with mild or moderate hepatic impairment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
隐形曼青的应助被科研通管家采纳,获得10
刚刚
鲨鱼辣椒完成签到,获得积分10
刚刚
桐桐的应助被科研通管家采纳,获得10
刚刚
丘比特的应助被科研通管家采纳,获得10
刚刚
打打的应助被科研通管家采纳,获得10
刚刚
顾矜的应助被科研通管家采纳,获得10
1秒前
1秒前
大个的应助被科研通管家采纳,获得10
1秒前
在水一方的应助被科研通管家采纳,获得10
1秒前
今后的应助被科研通管家采纳,获得10
1秒前
飞天小女警完成签到,获得积分10
1秒前
Maestro_S的应助被科研通管家采纳,获得10
1秒前
syvshc的应助被勇勇采纳,获得10
1秒前
婷婷小笑的应助被科研通管家采纳,获得10
1秒前
清洁能源动力驴完成签到,获得积分10
1秒前
我是老大的应助被科研通管家采纳,获得10
2秒前
2秒前
脑洞疼的应助被科研通管家采纳,获得10
2秒前
Lucas的应助被科研通管家采纳,获得10
2秒前
Hello的应助被科研通管家采纳,获得10
2秒前
赘婿的应助被科研通管家采纳,获得10
2秒前
冷酷以山的应助被科研通管家采纳,获得10
2秒前
molihuakai的应助被科研通管家采纳,获得10
2秒前
3秒前
思源的应助被科研通管家采纳,获得10
3秒前
田様的应助被科研通管家采纳,获得10
3秒前
3秒前
3秒前
3秒前
领导范儿的应助被科研通管家采纳,获得10
3秒前
3秒前
4秒前
guoguozhijia158完成签到,获得积分10
4秒前
丘比特的应助被科研通管家采纳,获得10
4秒前
秋风的应助被科研通管家采纳,获得20
4秒前
尺八发布了新的文献求助10
4秒前
在水一方的应助被科研通管家采纳,获得10
4秒前
华仔的应助被科研通管家采纳,获得10
4秒前
ZX801完成签到,获得积分10
4秒前
FashionBoy的应助被Irene采纳,获得10
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192078
求助须知:如何正确求助?哪些是违规求助? 9578698
关于积分的说明 21861559
捐赠科研通 7791583
什么是DOI,文献DOI怎么找? 3436814
关于科研通互助平台的介绍 2560538
邀请新用户注册赠送积分活动 2483582